Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Dose vs Conventional-Dose IMRT in Locally Advanced Nasopharyngeal Carcinoma After Induction Chemoimmunotherapy
NCT07328841Phase 3Recruiting
- Start
- Nov 2025
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in nasopharyngeal carcinoma (NPC) (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Started Nov 2025; status: recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07328841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328841.